Xenon Pharmaceuticals announces upcoming presentations at 2023 AAN

Xenon Pharmaceuticals announced its upcoming oral and poster presentations at the 2023 American Academy of Neurology, AAN, Annual Meeting in Boston, MA. 2023 AAN Presentation Details: Title: "XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b Study (X-TOLE) in Adults With Focal Epilepsy" Highlights: During the open-label extension, there was a sustained monthly reduction in seizure frequency from the double-blind period baseline. Seizure freedom for greater than or equal to6-month and greater than or equal to12-month consecutive durations was achieved in 17.5% and 10.5% of patients, respectively. Title: "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures" Highlights: Xenon has initiated a Phase 3 clinical trial, called X-ACKT, to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the double-blind period of XEN1101 compared to placebo.